Amoxillin-and pefloxacin-induced cholesterogenesis and phospholipidosis in rat tissues

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Rotimi, Solomon O ^a   Ojo, David A ^b   Talabi, Olusola A ^b   Ugbaja, Regina N ^b   Balogun, Elizabeth A ^b,c   Ademuyiwa, Oladipo ^b  

^a Centre for Economic Policy and Development Research   (Nigeria)

^b FEDERAL UNIVERSITY OF AGRICULTURE   (Nigeria)

^c UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

Amoxillin; Cholesterogenesis; Dyslipidemia; Pefloxacin; Phospholipidosis

Indexed keywords

AMOXICILLIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN; PEFLOXACIN; PHOSPHOLIPID; TRIACYLGLYCEROL; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; ANTIINFECTIVE AGENT; CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIET RESTRICTION; DOWN REGULATION; DYSLIPIDEMIA; ERYTHROCYTE; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPIDOSIS; MALE; NONHUMAN; RAT; UPREGULATION; ANIMAL; BIOSYNTHESIS; BLOOD; BRAIN CHEMISTRY; CARDIAC MUSCLE; CHEMISTRY; DRUG EFFECTS; KIDNEY; LIVER; LUNG; METABOLISM; SPLEEN;

ANIMALIA; RATTUS;

ACYL COENZYME A; AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; BRAIN CHEMISTRY; CHOLESTEROL; ERYTHROCYTES; KIDNEY; LIVER; LUNG; MALE; MYOCARDIUM; PEFLOXACIN; PHOSPHOLIPIDS; RATS; SPLEEN;

EID: 84924065909     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0011-8     Document Type: Article

References (49)

1. Chambers HF. Beta-Lactam and other cell wall and membrane active antibiotics. In: Katzung BG, editor. Basic and Clinical Pharmacology. 10th ed. New York: McGraw-Hill Companies Inc; 2007. p. 726-44.
2. Brodgen RN, Speight TN, Avery CS. Amoxillin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drug Met Lett. 1975;9:88-140.
3. Chambers HF. Sulfonamides, Trimethoprim and Quinolones. In: Katzung BG, editor. Basic and Clinical Pharmacology. 10th ed. New York: McGraw-Hill Companies Inc; 2007b. p. 763-70.
4. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone anti bacterials. Drug Saf. 1999;21:407-21.
5. Baselt R. Disposition of toxic drugs and chemicals in man. 8th ed. Foster City: Biomedical Publications; 2008. p. 81-3.
6. Cundiff J, Joe S. Amoxicillin-clavulanic acid-induced hepatitis. Am J Otolaryngol. 2007;28:28-30.
7. Owens Jr RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41 Suppl 2:S144-57.
8. Mulhall JP, Bergmann LS. Ciprofloxacin-induced acute psychosis. Urology. 1995;46:102-3.
9. Royer RJ, Pierfitte C, Netter P. Features of tendon disorders with fluoroquinolones. Therapie. 1994;49:75-6.
10. Simonin MA, Gegout-Pottie P, Minn A, Gillet P, Netter P, Terlain B. Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in pro teoglycan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother. 2000;44:867-72.
11. Ademuyiwa O, Ugbaja RN, Idumebor F, Adebawo O. Plasma lipid profiles and risk of cardiovascular disease in occupational lead exposure in Abeokuta, Nigeria. Lipids Health Dis. 2005;4:19.
12. Ademuyiwa O, Ugbaja RN, Rotimi SO. Plasma lipid profile, atherogenic and coronary risk indices in some residents of Abeokuta in south-western Nigeria. Biokemistri. 2008;20(2):85-91.
13. Ademuyiwa O, Agarwal R, Chandra R, Behari JR. Lead-induced phospholipidosis and cholesterogenesis in rat tissues. Chem Biol Interact. 2009;179:314-20.
14. Banjoko IO, Adeyanju MM, Ademuyiwa O, Adebawo OO, Olalere RA, Kolawole MO, et al. Hypolipidemic effects of lactic acid bacteria fermented cereal in rats. Lipids Health Dis. 2012;11:170.
15. Rotimi SO, Ojo DA, Talabi AO, Balogun EA, Ademuyiwa O. Tissue dyslipidemia in salmonella-infected rats treated with amoxillin and pefloxacin. Lipids Health Dis. 2012;11:152.
16. Afolabi OK, Wusu AD, Ogunrinola OO, Abam EO, Babayemi DO, Dosumu OA, et al. Paraoxonase 1 activity in sub chronic low-level inorganic arsenic exposure through drinking water. Environ Toxicol. 2014. In press. doi:10.1002/tox.22030.
17. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497-509.
18. Rose HG, Oklander M. Improved procedure for the extraction of lipids from human erythrocytes. J Lipid Res. 1965;6:428-31.
19. Hanahan DJ, Ekholm JE. The preparation of red cell ghosts (membranes). In: Fleischer S, Packer L, editors. Methods in enzymology vol. 31. Biomembranes, Part A. New York: Academic Press; 1974. p. 168-72.
20. Rao AV, Ramakrishnan S. Indirect assessment of hydro xymethylglutaryl-CoA reductase (NADPH) activity in liver tissue. Clin Chem. 1975;21:1523-5.
21. Ginsberg HN. Lipoprorein metabolism and its relationship to atherosclerosis. Med Clin North Am. 1994;78:1-20.
22. Glew RH, Kassam HA, Bhanji RA, Okorodudu A, VanderJagt DJ. Serum lipid profiles and risk of cardiovascular disease in three different male populations in northern Nigeria. J Health Popul Nutr. 2002;20:166-74.
23. Abe A, Hiraoka M, Shayman JA. A role for lysosomal phospholipase A2 in drug-induced phospholipidosis. Drug Met Lett. 2007;1:49-53.
24. Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol. 1997;25:53-60.
25. Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005;83:282-92.
26. Newsholm EA, Start C. Regulation in metabolism. Chichester: John Wiley and Sons; 1981.
27. Botham KM, Mayes PA. Metabolism of acylglycerols and sphingolipids. In: Murray RK, Granner DK, Rodwell VW, editors. Harpers Illustrated Biochemistry. 27th ed. New York: McGraw Hill Companies Inc; 2006. p. 209-16.
28. Kurokawa K, Nagami GT, Yamaguchi DT. Transport and substrate metabolism of the kidney. Amsterdam: Elsevier Science Publishers B. V. Biomedical Division; 1985.
29. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343-51.
30. Mermier P, Baker N. Flux of free fatty acids among host tissues, ascites fluid, and Ehrlich ascites carcinoma cells. J Lipid Res. 1974;15:339-51.
31. Allen DW, Manning N. Abnormal phospholipid metabolism in spur cell anaemia.: decreased fatty acid incorporation into phosphatidylethanolamine and increased incorporation into acylcarnitine in spur cell anemia erythrocytes. Blood. 1994;84:1283-7.
32. Suda T, Akamatsu A, Nakaya Y, Masuda Y, Desaki J. Alterations in erythrocyte membrane lipid and its fragility in a patient with familial lecithin: cholesterol acyltrasferase (LCAT) deficiency. J Med Invest. 2002;49:147-55.
33. Van Deenen LLM, De Gier J. Lipids of the red cell membrane. In: Surgenor DN, editor. The red blood cell, vol. 1. 2nd ed. New York: Academic; 1974. p. 147-268.
34. Hsiao LL, Howard RJ, Aikawa M, Taraschi TF. Modification of host cell membrane lipid composition by the intra-erythrocytic human malaria parasite Plasmodium falciparum. Biochem J. 1991;274(Pt 1):121-32.
35. Malhotra KT, Malhotra K, Lubin BH, Kuypers FA. Identification and molecular characterization of acyl-CoA synthetase in human erythrocytes and erythroid precursors. Biochem J. 1999;344(Pt 1):135-43.
36. Czarnecka H, Yokoyama S. Regulation of cellular cholesterol efflux by lecithin: cholesterol acyl trans ferase reaction through nonspecific lipid exchange. J Biol Chem. 1996;271:2023-8.
37. Lange Y, Molinaro AL, Chauncey TR, Steck TL. On the mechanism of transfer of cholesterol between human erythrocytes and plasma. J Biol Chem. 1983;258:6920-6.
38. Nikolic M, Stanic D, Baricevic I, Jones DR, Nedic O, Niketic V. Efflux of cholesterol and phospholipids derived from the haemoglobin-lipid adduct in human red blood cells into plasma. Clin Bio chem. 2007;40:305-9.
39. Steck TL, Kezdy FJ, Lange Y. An activation-collision mechanism for cholesterol transfer between membranes. J Biol Chem. 1988;263:13023-31.
40. Nikolic M, Stanic D, Antonijevic N, Niketic V. Cholesterol bound to haemoglobin in normal human erythrocytes: a new form of cholesterol in circulation. Clin Bio chem. 2004;37:22-6.
41. Meurs I, Hoekstra M, van Wanrooij EJ, Hildebrand RB, Kuiper J, Kuipers F, et al. HDL cholesterol levels are an important factor for determining the lifespan of erythrocytes. Exp Hematol. 2005;33:1309-19.
42. Brown MS, Goldstein JL, Dietschy JM. Active and inactive forms of 3-hydroxy-3-methlglutarylcoenzyme A reductase in the liver of the rat. Comparison with the rate of cholesterol synthesis in different physiological states. J Biol Chem. 1979;254:5144-9.
43. Kennelly PJ, Rodwell VW. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by reversible phosphorylation-dephosphorylation. J Lipid Res. 1985;26:903-14.
44. Rodwell VW, Nordstrom JL, Mitschelen JJ. Regulation of HMG-CoA reductase. Adv Lipid Res. 1976;14:1-74.
45. Clegg RJ, Middleton B, Bell GD, White DA. The mechanism of cyclic monoterpene inhibition of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase in vivo in the rat. J Biol Chem. 1982;257:2294-9.
46. Dugan RE, Baker TA, Porter JW. Regulation of short-term changes in hepatic beta-hydroxy-beta-methylglutaryl-CoA reductase activity. Eur J Biochem. 1982;125:497-503.
47. Kleinsek DA, Jabalquinto AM, Porter JW. In vivo and in vitro mechanisms regulating rat liver beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity. J Biol Chem. 1980;255:3918-23.
48. Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med (Maywood). 2001;226:825-30.
49. Joshi UM, Kodavanti PR, Coudert B, Dwyer TM, Mehendale HM. Types of interaction of amphiphilic drugs with phospholipid vesicles. J Pharmacol Exp Ther. 1988;246:150-7.